CORONA Q4 FY26 results at a glance
CORONA REMEDIES LIMITED Q4 FY26 key results metrics| Quarter | Q4 FY26 |
|---|
| Quarter ended | 31 Mar 2026 |
|---|
| Revenue | ₹353 cr |
|---|
| Revenue YoY | +20.2% |
|---|
| Operating profit | ₹51.73 cr |
|---|
| Operating margin | 14.7% |
|---|
| Net profit | ₹45.33 cr |
|---|
| Net profit YoY | +43.7% |
|---|
| Net profit QoQ | +9.8% |
|---|
| Net margin | 12.8% |
|---|
| Basic EPS | ₹7.41 |
|---|
| TTM revenue | ₹1,335 cr |
|---|
| TTM net profit | ₹164 cr |
|---|
| TTM net margin | 12.3% |
|---|
CORONA Q4 FY26 results: what the numbers say
CORONA REMEDIES LIMITED (CORONA) has reported its Q4 FY26 results for the quarter ended 2026-03-31. The company posted revenue of ₹353 cr and a net profit of ₹45.33 cr, translating into earnings per share of ₹7.41.
Compared with the same quarter a year earlier, revenue grew strongly by +20.2% and net profit grew strongly by +43.7%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹51.73 cr, an operating margin of 14.7% versus 15.0% a year ago — a contraction of 0.4 percentage points.
CORONA quarter-wise results table
Net profit
₹45.33 cr
+43.7% YoY
Operating profit
₹51.73 cr
+17.1% YoY
CORONA REMEDIES LIMITED (CORONA) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q4 FY262026-03-31 | ₹353 cr | ₹51.73 cr | ₹45.33 cr | 14.7% | 12.8% | ₹7.41 | +43.7% | +9.8% |
| Q3 FY262025-12-31 | ₹342 cr | ₹73.71 cr | ₹41.27 cr | 21.5% | 12.1% | ₹6.75 | -8.2% | -10.7% |
| Q1 FY262025-06-30 | ₹346 cr | ₹61.05 cr | ₹46.2 cr | 17.6% | 13.3% | ₹7.55 | — | +46.4% |
| Q4 FY252025-03-31 | ₹294 cr | ₹44.18 cr | ₹31.55 cr | 15.0% | 10.7% | ₹5.16 | — | -29.8% |
| Q3 FY252024-12-31 | ₹298 cr | ₹59.73 cr | ₹44.95 cr | 20.1% | 15.1% | ₹7.35 | — | — |
| TTM (last 4 quarters) | ₹1,335 cr | ₹231 cr | ₹164 cr | 17.3% | 12.3% | ₹26.87 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
CORONA quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
CORONA REMEDIES LIMITED quarterly income statement| Particulars | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 | Q4 FY252025-03-31 | Q3 FY252024-12-31 |
|---|
| Revenue / Sales | ₹353 cr | ₹342 cr | ₹346 cr | ₹294 cr | ₹298 cr |
|---|
| Total expenses | ₹301 cr | ₹269 cr | ₹285 cr | ₹250 cr | ₹238 cr |
|---|
| Gross profit | ₹287 cr | ₹282 cr | ₹281 cr | ₹237 cr | ₹242 cr |
|---|
| Operating profit (EBIT) | ₹51.73 cr | ₹73.71 cr | ₹61.05 cr | ₹44.18 cr | ₹59.73 cr |
|---|
| Operating margin | 14.7% | 21.5% | 17.6% | 15.0% | 20.1% |
|---|
| Interest cost | ₹1.38 cr | ₹1.66 cr | ₹1.39 cr | ₹2.2 cr | ₹2.39 cr |
|---|
| Profit before tax | ₹54.74 cr | ₹55.21 cr | ₹60.69 cr | ₹43.61 cr | ₹58.28 cr |
|---|
| Tax expense | ₹9.41 cr | ₹13.94 cr | ₹14.5 cr | ₹12.06 cr | ₹13.33 cr |
|---|
| Effective tax rate | 17.2% | 25.2% | 23.9% | 27.7% | 22.9% |
|---|
| Net profit (PAT) | ₹45.33 cr | ₹41.27 cr | ₹46.2 cr | ₹31.55 cr | ₹44.95 cr |
|---|
| Net profit margin | 12.8% | 12.1% | 13.3% | 10.7% | 15.1% |
|---|
| Basic EPS | ₹7.41 | ₹6.75 | ₹7.55 | ₹5.16 | ₹7.35 |
|---|
| Diluted EPS | ₹7.41 | ₹6.75 | ₹7.55 | ₹5.16 | ₹7.35 |
|---|
CORONA results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q4 FY26 | Q3 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 |
|---|
| Revenue YoY | +20.2% | +15.0% | — | — | — |
|---|
| Revenue QoQ | +3.1% | -1.1% | +17.9% | -1.3% | — |
|---|
| Operating profit YoY | +17.1% | +23.4% | — | — | — |
|---|
| Operating profit QoQ | -29.8% | +20.7% | +38.2% | -26.0% | — |
|---|
| Net profit YoY | +43.7% | -8.2% | — | — | — |
|---|
| Net profit QoQ | +9.8% | -10.7% | +46.4% | -29.8% | — |
|---|
| EPS YoY | +43.6% | -8.2% | — | — | — |
|---|
| EPS QoQ | +9.8% | -10.6% | +46.4% | -29.8% | — |
|---|
CORONA annual results history
Full-year performance for CORONA REMEDIES LIMITED, useful for reading each quarter in context.
CORONA REMEDIES LIMITED annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹1,401 cr | ₹1,196 cr | ₹1,014 cr | ₹884 cr |
|---|
| Total expenses | ₹1,145 cr | ₹992 cr | ₹886 cr | ₹775 cr |
|---|
| Gross profit | ₹1,141 cr | ₹959 cr | ₹787 cr | ₹673 cr |
|---|
| Operating profit (EBIT) | ₹256 cr | ₹204 cr | ₹128 cr | ₹108 cr |
|---|
| Operating margin | 18.3% | 17.0% | 12.6% | 12.2% |
|---|
| Interest cost | ₹4.57 cr | ₹8.04 cr | ₹11.5 cr | ₹2.39 cr |
|---|
| Profit before tax | ₹240 cr | ₹199 cr | ₹118 cr | ₹111 cr |
|---|
| Tax expense | ₹55.3 cr | ₹49.1 cr | ₹27.98 cr | ₹25.96 cr |
|---|
| Effective tax rate | 23.0% | 24.7% | 23.6% | 23.4% |
|---|
| Net profit (PAT) | ₹185 cr | ₹149 cr | ₹90.5 cr | ₹84.93 cr |
|---|
| Net profit margin | 13.2% | 12.5% | 8.9% | 9.6% |
|---|
| Basic EPS | ₹30.27 | ₹24.43 | ₹14.80 | ₹13.89 |
|---|
| Diluted EPS | ₹30.27 | ₹24.43 | ₹14.80 | ₹13.89 |
|---|
Revenue trend and demand read-through
Topline for Q4 FY26 came in at ₹353 cr against ₹294 cr in Q4 FY25, and ₹342 cr in the preceding Q3 FY26 quarter.
On a sequential basis revenue grew +3.1%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹301 cr, or 85.3% of revenue, with operating profit grew +17.1% year on year.
Margins, tax and profitability
Net profit of ₹45.33 cr works out to a net margin of 12.8% compared with 10.7% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, CORONA REMEDIES LIMITED reported profit before tax of ₹54.74 cr, a tax charge of ₹9.41 cr (effective rate 17.2%), interest cost of ₹1.38 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹41.27 cr in Q3 FY26 to ₹45.33 cr in Q4 FY26, a change of +9.8%.
Trailing twelve months and annual context
Across the trailing four quarters CORONA REMEDIES LIMITED has generated revenue of ₹1,335 cr and net profit of ₹164 cr, a trailing net margin of 12.3%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹1,401 cr with net profit of ₹185 cr and EPS of ₹30.27, versus the prior year where revenue grew +17.2% and profit grew +23.9%.
What to watch in the next CORONA quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
CORONA REMEDIES LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
CORONA results coverage
No results report published for CORONA yet — our desk covers each quarter within minutes of the filing.
CORONA quarterly results FAQs
What were CORONA REMEDIES LIMITED (CORONA) Q4 FY26 results?
In Q4 FY26 (quarter ended 31 Mar 2026), CORONA REMEDIES LIMITED reported revenue of ₹353 cr and net profit of ₹45.33 cr, a change of +43.7% year on year on +20.2% revenue growth. EPS stood at ₹7.41.
What is CORONA profit margin in Q4 FY26?
CORONA REMEDIES LIMITED posted a net profit margin of 12.8% and an operating margin of 14.7% in Q4 FY26. On a trailing twelve-month basis, revenue is ₹1,335 cr and net profit ₹164 cr.
Did CORONA results beat the previous quarter?
CORONA REMEDIES LIMITED net profit changed +9.8% quarter on quarter, from ₹41.27 cr in Q3 FY26 to ₹45.33 cr in Q4 FY26.
When are CORONA REMEDIES LIMITED (CORONA) quarterly results?
CORONA REMEDIES LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see CORONA latest quarterly results?
Results coverage for CORONA will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the CORONA stock page.
What is CORONA REMEDIES LIMITED annual revenue and profit?
For FY26, CORONA REMEDIES LIMITED reported full-year revenue of ₹1,401 cr and net profit of ₹185 cr, with EPS of ₹30.27.
How many quarterly results has CORONA declared recently?
Past results dates for CORONA will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
